Incident Response Report 2024

In the past year, threat actors have been making larger and faster moves that are able to damage their targets.

This report by Palo Alto Networks, a Criticaleye Partner, discusses emerging threats for businesses and how to face them, whilst also exploring how threat actors gain access to organisations, what they do once they get in and top recommendations for how to stop these.

Key takeaways include:

  • Attackers are now beginning to exfiltrate data in hours as opposed to days. Respondents and defenders need to speed up their own responses
  • Software vulnerabilities still matter. It's important to measure your threat surface, then fix it quickly and comprehensively
  • Threat actors are becoming more sophisticated, organised, knowledgeable and able to use IT, cloud and security tools as weapons of offense




Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.

Inspiring Leaders Podcast: Le...

Rob Hornby, Co-CEO of AlixPartners and Rita Clifton CBE, Portfolio Chair and Non-Executive Director (including Deputy Chair of the John Lewis Partnership, Chair of Simplyhealth, Chair of the international sustainability...

Inspiring Leaders Podcast: De...

Lucinda Charles-Jones, Non-executive Director & Chair or RemCo for Virgin Money and Rank Group (plus a Criticaleye Board Mentor) and Jim Devine, Group HRD, Spirax Group speak to us about some of the findings of our ...

Click here to download this insight
The Boards' Cyber-Risk Compas...

In this insight, Criticaleye Retreat Partner Palo Alto Networks shares the 10 questions every director should ask to govern, fortify and strategise their organisation’s approach to cyber risk.


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 429




Hitachi Solutions Accenture Concentrix E.ON UK Worldpay Google Lightsource bp NatWest Group Palo Alto Networks London Stock Exchange Group FTSE Women Leaders Review AlixPartners Legal & General IBM Consulting NATS British Land Salesforce Eightfold AI Workday Rolls-Royce Drax Group plc Aldermore Group GlaxoSmithKline plc